Literature DB >> 8397764

Humanized antibodies.

G Winter1, W J Harris.   

Abstract

Hybridoma technology enabled rodent monoclonal antibodies to be created against human pathogens and cells, but these had limited clinical utility. Protein engineering is now generating antibodies for treatment of infectious disease, autoimmune disease and cancer by 'humanizing' rodent antibodies. Humanized antibodies have improved pharmacokinetics, reduced immunogenicity and have been used to clinical advantage.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8397764     DOI： 10.1016/0167-5699(93)90039-N

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  18 in total

Review 1.  [Update of rheumatology--II. State and prospectives of chemotherapy in chronic arthritis].

Authors:  G Hein; T Eidner; P Oelzner; B Manger
Journal:  Med Klin (Munich)       Date:  1999-10-15

2.  Development of human monoclonal antibodies: A review.

Authors:  T Lindl
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

Review 3.  Anti-CD4 monoclonal antibodies in rheumatoid arthritis.

Authors:  E H Choy; G H Kingsley; G S Panayi
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Construction and expression of single-chain Fv antibody against human bladder carcinoma.

Authors:  L Z Yu; S Xiao; H L Huang; Z Gu; F L Gu; Y L Guo
Journal:  Urol Res       Date:  1996

Review 5.  Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases.

Authors:  P C Taylor
Journal:  Mol Biotechnol       Date:  2001-10       Impact factor: 2.695

Review 6.  The biotechnology and applications of antibody engineering.

Authors:  R Rapley
Journal:  Mol Biotechnol       Date:  1995-04       Impact factor: 2.695

Review 7.  Cytokines.

Authors:  H Holtmann; K Resch
Journal:  Naturwissenschaften       Date:  1995-04

Review 8.  TNF-alpha and its inhibitors in cancer.

Authors:  Inès Zidi; Souhir Mestiri; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

9.  Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics.

Authors:  Stephen Thompson; John Dessi; Colin H Self
Journal:  MAbs       Date:  2009-07-19       Impact factor: 5.857

10.  Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.

Authors:  J K J Ahlskog; C Schliemann; J Mårlind; U Qureshi; A Ammar; R B Pedley; D Neri
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.